Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation
暂无分享,去创建一个
[1] J. Camm,et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[2] P. Noseworthy,et al. Stroke Prevention in Nonvalvular Atrial Fibrillation: A Stakeholder Perspective. , 2018, Journal of the American College of Cardiology.
[3] P. Sengupta,et al. Percutaneous Closure of Peridevice Leak After Left Atrial Appendage Occlusion. , 2018, JACC. Cardiovascular interventions.
[4] R. Akehurst,et al. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non–Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation , 2018, Stroke.
[5] D. Holmes,et al. Burden of Atrial Fibrillation-Associated Ischemic Stroke in the United States. , 2018, JACC. Clinical electrophysiology.
[6] Pascal Defaye,et al. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[7] K. Chun,et al. Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[8] K. Ellenbogen,et al. PROCEDURAL SAFETY OF WATCHMAN IMPLANTATION: THE US NESTED POST APPROVAL STUDY , 2018 .
[9] S. Bangalore,et al. Device Thrombosis After Percutaneous Left Atrial Appendage Occlusion Is Related to Patient and Procedural Characteristics but Not to Duration of Postimplantation Dual Antiplatelet Therapy , 2018, Circulation. Cardiovascular interventions.
[10] Christopher R. Ellis,et al. Angiographic Efficacy of the Atriclip Left Atrial Appendage Exclusion Device Placed by Minimally Invasive Thoracoscopic Approach. , 2017, JACC. Clinical electrophysiology.
[11] J. Saw,et al. Residual leaks following percutaneous left atrial appendage occlusion: assessment and management implications. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[12] Saibal Kar,et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.
[13] J. Rodés‐Cabau,et al. Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes , 2017, Circulation. Cardiovascular interventions.
[14] Mircea Cinteza,et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial , 2017, The Lancet.
[15] V. Reddy,et al. TCT-188 Budget Impact of Stroke Reduction Strategies in Atrial Fibrillation: Medicare and Patient Perspectives , 2017 .
[16] S. Kische,et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.
[17] S. Kubo,et al. Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients. , 2017, JACC. Clinical electrophysiology.
[18] W. Schillinger,et al. Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding (from the Amplatzer Cardiac Plug Multicenter Registry). , 2017, The American journal of cardiology.
[19] G. Lip,et al. Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry , 2017, Stroke.
[20] J. Saw,et al. The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. , 2017, American heart journal.
[21] M. Rosenqvist,et al. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[22] Xiaoxi Yao,et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. , 2017, Journal of the American College of Cardiology.
[23] B. Meier,et al. Patients with intracranial bleeding and atrial fibrillation treated with left atrial appendage occlusion: Results from the Amplatzer Cardiac Plug registry. , 2017, International journal of cardiology.
[24] J. Nielsen-Kudsk,et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[25] Michael J Pencina,et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation , 2017, JAMA.
[26] W. O’Neill,et al. Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.
[27] A. Magalski,et al. Transesophageal echocardiographic diagnosis of a WATCHMAN left atrial appendage closure device thrombus 10 years following implantation , 2017, Echocardiography.
[28] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[29] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[30] S. Bertog,et al. Catheter‐based closure of residual leaks after percutaneous occlusion of the left atrial appendage , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[31] P. Neužil,et al. Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation. , 2016, Journal of the American College of Cardiology.
[32] M. Turakhia,et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. , 2016, JAMA cardiology.
[33] B. Meier,et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. , 2016, International journal of cardiology.
[34] B. Meier,et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[35] Roger D. White,et al. Left Atrial Appendage Patency at Cardioversion After Surgical Left Atrial Appendage Intervention. , 2016, The Annals of thoracic surgery.
[36] G. Caleb Alexander,et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation , 2016, Journal of the American Heart Association.
[37] B. Meier,et al. Comparison of Efficacy and Safety of Left Atrial Appendage Occlusion in Patients Aged <75 to ≥ 75 Years. , 2016, The American journal of cardiology.
[38] R. Akehurst,et al. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. , 2015, Journal of the American College of Cardiology.
[39] E. Dolan,et al. Rates and Determinants of 5-Year Outcomes After Atrial Fibrillation–Related Stroke: A Population Study , 2015, Stroke.
[40] Randall J. Lee,et al. Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design. , 2015, American heart journal.
[41] P. O’Neill,et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. , 2015, Heart rhythm.
[42] I. V. Van Gelder,et al. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry , 2014, Circulation.
[43] Petr Neuzil,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.
[44] V. Reddy,et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. , 2013, Journal of the American College of Cardiology.
[45] P. Neužil,et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial , 2013, Circulation.
[46] P. Neužil,et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial , 2013 .
[47] Andrea Natale,et al. Percutaneous Closure of the Left Atrial Appendage. , 2012, Cardiac electrophysiology clinics.
[48] Saibal Kar,et al. Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.
[49] J. Sturdivant,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2010 .
[50] Maurice Buchbinder,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.
[51] W. Edwards,et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction? , 1996, The Annals of thoracic surgery.
[52] B. D. Lindsay,et al. Obliteration of the left atrial appendage: a concept worth testing. , 1996, The Annals of thoracic surgery.
[53] J. Odell,et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.